In addition, outcomes of the KEYNOTE189 shows that patients receiving immunotherapy plus chemotherapy have longer mPFS than those receiving chemotherapy (9 vs. 5 months, HR=0.47,95%CI [0.29-0.77]) in KRAS -mutated lung cancer (21). Here, KRAS is linked to lung carcinoma.